

Abstracts of papers presented
at the 2026 Cold Spring Harbor Asia Conference

CANCER IMMUNOTHERAPY

September 7–September 11, 2026

Arranged by

Gabrielle Belz, *The University of Queensland Diamantina Institute*

Xuetao Cao, *Chinese Academy of Medical Sciences*

Sidonia Fagarasan, *Kyoto University*

Yang-xin Fu, *Tsinghua University*

Guido Kroemer, *Centre de Recherche des Cordeliers*



Cold Spring Harbor Conferences Asia
Cold Spring Harbor Laboratory



CANCER IMMUNOTHERAPY

Monday, September 7 – Friday, September 11, 2026

Monday	7:00 pm	1 Keynote Session
Tuesday	9:00 am	2 Tumor Immune Escape and Immunosuppression
Tuesday	2:00 pm	Poster Session
Tuesday	7:00 pm	3 Targeting Cell Death for Cancer Immunotherapy
Wednesday	9:00 am	4 Integrative Strategies in Cancer Immunotherapy
Wednesday	1:30 pm	<i>Visit to Old Suzhou</i>
Wednesday	7:00 pm	5 Cancer Vaccines
Thursday	9:00 am	6 Primary and Acquired Resistance to Cancer Immunotherapy
Thursday	11:15 am	7 Cytokine, Antibody and Cell Engineering in Cancer Immunotherapy
Thursday	2:00 pm	8 New Approaches to Cancer Immunotherapy
Thursday	5:00 pm	<i>Cocktails and Banquet</i>
Friday		<i>Departure</i>

Oral presentation sessions are located in the CSHA Auditorium

Poster session is in the Lake Front Hall.

Cocktail social hour is held in the Grand Ballroom Foyer

Old Suzhou visits depart from the CSHA lobby

**optional tour requires additional fee.*

Meal locations and times are as follows:

Lunch: Main Cafeteria 12:00am - 1:30pm

Dinner: Main Cafeteria 6:00pm - 7:30pm

Banquet: Grand Ballroom 6:00 pm

More information will be available at CSHA office.

(Map at the end of this abstract book)

PROGRAM

MONDAY, September 7—7:00 PM

SESSION 1 KEYNOTE SESSION

Chairperson: **Xuetao Cao**, Chinese Academy of Medical Sciences, Beijing, China

Engineering T cells to go where natural evolution hasn't—Toward sustained function in the TME

Philip D. Greenberg, Yapeng Su, Thomas M. Schmitt, Jihoon W. Lee, Sammy Barkal, Daniel Chen, Ashley Thelen, Shannon K. Oda, E. Gabriela Chiorean, Philip Bradley, Aude G. Chapuis [35'+10']
Presenter affiliation: Fred Hutchinson Cancer Center, Seattle, Washington; University of Washington, Seattle, Washington; Parker Institute for Cancer Immunotherapy, Seattle, Washington.

1

CD8 T cell tumor immunity without tumor antigens

Judy Lieberman [35'+10']
Presenter affiliation: Boston Children's Hospital, Boston, Massachusetts.

2

TUESDAY, September 8—9:00 AM

SESSION 2 TUMOR IMMUNE ESCAPE AND IMMUNOSUPPRESSION

Chairperson: **Xuetao Cao**, Chinese Academy of Medical Sciences, Beijing, China
Sidonia Fagarasam, Kyoto University, Kyoto, Japan

Metabolic regulatory pathways and anti-cancer responses

Sidonia Fagarasan, Masaki Tajima, Zhang Baihao [20'+10']
Presenter affiliation: Kyoto University Graduate School of Medicine, Kyoto, Japan; Laboratory for Mucosal Immunity, Yokohama, Japan.

3

Nucleic acid innate immunity in tumor immune escape and immunotherapy

Xuetao Cao [20'+10']
Presenter affiliation: Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

4

Tumor-selective blockade of CD47 via DYRK1A inhibition restores cancer immune surveillance.

Eric Wang, Sadik Karma, Alexander Arnuk, Cuijuan Han, Sakthi Harini Rajendran, Omar Abdel-Wahab [10'+5']

Presenter affiliation: The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut. 5

Mitochondrial FAO as a metabolic checkpoint in antitumor T cell immunity

Kenji Chamoto [20'+10']

Presenter affiliation: CCI, Kyoto University Graduate School of Medicine, Kyoto, Japan. 6

Break

Immunosuppressive programming of tertiary lymphoid structures by regulatory T cells determines clinical outcomes in HBV-associated hepatocellular carcinoma

Furong Liu, Zuyan Fan, Weifeng Zeng, Xiru Zhang, Zhiheng Ji, Deli Huang, Zhanguo Zhang, Wenjing Su [10'+5']

Presenter affiliation: Zhejiang University, Hangzhou, China. 7

ZFAND5 deficiency drives tumor-infiltrating and persistence of TCR-based CAR-T cells against solid tumors

Hongtao Liu, Huimin Wang, Jiasheng Wang, Xin Lin [10'+5']

Presenter affiliation: Changping Laboratory, Beijing, China. 8

Dark kinases as checkpoint molecules that regulate induction of anti-tumor immunity

Vijay K. Kuchroo [20'+10']

Presenter affiliation: Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts; Broad Institute of MIT and Harvard, Cambridge, Massachusetts. 9

Targeting DGKα/PA axis inhibits tumor immune evasion and augments sensitivity to immunotherapy in gastrointestinal cancers

Jie Chen, Siqi Liu, Ting Peng, Fenglong Wang, Yuheng Zhu, Jingyuan Pang, Qingnan Wu, Yan Wang, Qimin Zhan [10'+5']

Presenter affiliation: Peking University Cancer Hospital & Institute, Beijing, China; Peking University, Beijing, China; Soochow University, Suzhou, China. 10

POSTER SESSION

Integrated clinical and spatial transcriptomic characterization of MSI, MSS, and EMAST/MSI colorectal cancers in African American patients and therapeutic choice

Shweta Dixit, Hassan Brim, Khushi Desai, Jonathan Chen, Elham Azizi, Hassan Ashktorab

Presenter affiliation: Howard University, Washington , DC.

11

m⁶A-mediated epitranscriptomic regulation in DC1-like cell fate acquisition

Leona Brandl, Anke Heit-Mondrzyk, Nejc Arh, Filipe Pereira, Michaela Frye

Presenter affiliation: German Cancer Research Center (DKFZ), Heidelberg, Germany.

12

Systematic screening of mRNA lipid nanoparticles for t-cell engineering

Taiying Chen, Peter Moyle, Sherry Y. Wu

Presenter affiliation: The University of Queensland, Brisbane, Australia.

13

Identification of a novel tumour-intrinsic regulator of immune evasion and natural killer cell resistance

Gloryn Chia, Malini Rethnam, Yi Ren, Cyrus Cheng, Evelyn Saudjana, Soon Chai Loo

Presenter affiliation: National University of Singapore, Singapore.

14

An integrative NK-HAMC hydrogel platform for glioblastoma immunotherapy with in situ metabolic monitoring via CEST MRI

Kaihang Deng, Tian Zhang, Hao Zhang, Huabing Liu, Yuan Zong, Aiping Lyu, Kannie W.Y. Chan, Wai Po Chong

Presenter affiliation: Hong Kong Baptist University, Hong Kong, China.

15

High-plex spatial profiling reveals metabolic and cellular heterogeneity in the oesophageal tumour microenvironment

Trayee Dhar, Sandra Brosda, James Monkman, Arutha Kulasinghe, Andrew Barbour, Lauren Aoude

Presenter affiliation: The University of Queensland, Brisbane, Australia.

16

High-throughput mechano-engineering of TCRs for precise cancer immunotherapy <u>Yushen Du</u> , Wei Hu, Jingyu Fan, Guofu Shang, Songfang Wu, Yuting Li, Tongtong Zhang, Nuo Liu, Yushen Lin, Wenbin Zhao, Ji Cao, Weiwei Yin, Xiaolong Li, Zhenhai Li, Jizhong Lou, Wei Chen Presenter affiliation: Zhejiang University, Hangzhou, China.	17
Frenemy pathways in cancer—Exploiting apoptosis–interferon antiviral response antagonism with oncolytic viruses to induce immunogenic cell death. Vladimir Bozhdansky, Eran Bacharach, <u>Marcelo Ehrlich</u> Presenter affiliation: Tel Aviv University, Tel Aviv, Israel.	18
Activation-triggered, self-reinforcing CCL5–CCR5 relay drives CAR T cell swarming and immune remodeling in solid tumors Qiaomin Hua, <u>Xiaoli Fan</u> , Yulan Weng, Ying Huang, Ai-Qin Huang, Lingyan Zhu, Yang Xu, Biro Maté, Xiaoshan Shi, Limin Zheng, Chong Wu Presenter affiliation: Sun Yat-sen University, Guangzhou, China.	19
A glycosylation signature predicts response to immune checkpoint blockade in NSCLC across tissue and plasma <u>Yu A. Guo</u> , Aaron C. Tan, Tanmay Kulshrestha, Denis Odinkov, Dawn P. Lau, Lan Ying Wang, Lena Kwok, Timothy K. Tay, Yiqing Huang, Daniel S. Tan, Anders J. Skanderup Presenter affiliation: Genome Institute of Singapore, Singapore.	20
Engineered anti-HER2 antibody variants with modulated fab and fc affinities reveal distinct ADCC and ADCP profiles across diverse solid tumor microenvironments <u>Joonsang Ha</u> , Junsang Doh, Sang Taek Jung Presenter affiliation: Seoul National University, Seoul, South Korea.	21
Orosomucoid-2 acts as a double-edged sword in early sensing and progression of colorectal cancer <u>Doudou Huang</u> , Yuzhao Jin, Chenyue Yang, Lan Shen, Qian Xiao Presenter affiliation: The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.	22
Tumor microenvironment driven T4 liberation promotes Treg mediated immunosuppression via integrin $\alpha\beta3$ signaling <u>Tianning Huang</u> , Jian Gu Presenter affiliation: The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.	23

GPR43 controls functional plasticity of tumor-associated neutrophils in lung cancer

Jae-Gon Kim, You-Me Kim

Presenter affiliation: Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea.

24

Microneedle patch-aided intratumor co-delivery of FOLFIRINOX, surufatinib and α PD-1 for synergistic efficacy of combined chemo- and immuno-therapy of PDAC

Tingting Kong, Ximo Xu, Fei Wu, Tuo Jin, Yan Zheng, Jiang Long

Presenter affiliation: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

25

Malignant ascites harbor tumor-reactive T cells enabling intraperitoneal immunotherapy in metastatic gastric cancer

Changsong Qi, Fan Yang, Yangshijia Liu, Tetsuichi Kansha, Yi Lai, Chang Liu, Huijuan Guo, Jiarui Li, Yanshuo Cao, Yunfei Song, Wanjun Song, Xu Zhang, Jun Yong, Weifeng Lai, Zeyu Chen, Lin Shen
Presenter affiliation: Peking University Health Science Center, Beijing, China.

26

Potentiating adoptive cell therapy using membrane-bound IL-7 and TGF β R2 blockade

Ling Lan, Jiasheng Wang, Xin Lin

Presenter affiliation: Changping Laboratory, Beijing, China.

27

Campylobacter gracilis drives malignant progression and immunosuppression of esophageal squamous cell carcinoma via focal adhesion kinase axis

Siqi Liu, Zixuan Bu, Fenglong Wang, Qimin Zhan, Jie Chen

Presenter affiliation: Peking University Cancer Hospital & Institute, Beijing, China; Peking University, Beijing, China.

28

α TIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity via rejuvenating tumor infiltrating T cells

Xiangming Liu, Nan Li, Yumeng Chen, Zijun Xie, Tao Huang, Shijie Li, Xinxin Wang, Ruiqi Zhang, Xiaohong Yu, Huiqin Meng, Jingya Guo, Yang Liu, Yang-xin Fu, Zaopeng Yang

Presenter affiliation: Changping Laboratory, Beijing, China; Tsinghua University, Beijing, China.

29

Stearic acid from lipid-laden neutrophils induces macrophage IL-36 γ production to suppress tumor progression

Xingchen Liu, Baixi Zhu, Limin Zheng, Yan Wu

Presenter affiliation: Sun Yat-sen University, Guangzhou, China.

30

Modelling the immunosuppressive ovarian tumour microenvironment using patient ascites-derived organoids <u>G M Shazzad Hossain Prince</u> , John D Hooper, Sherry Y. Wu Presenter affiliation: The University of Queensland, Brisbane, Australia.	31
IT1 mediates NK cell immune evasion in MHC-i-deficient tumors <u>Malini Rethnam</u> Presenter affiliation: National University of Singapore, Singapore.	32
Tumour-derived metabolites posttranscriptionally hijack macrophage to restrain Th1-mediated anti-tumour immunity <u>Xingyu Rong</u> , Hai Wang, Osamu Takeuchi Presenter affiliation: Kyoto University, Kyoto, Japan.	33
Redox-dependent regulation of PD-L1 and MHC-i expression by cold atmospheric microplasma in tumor cells Rubaiya Islam, Otoha Shimmachi, Farhana Begum, Mahedi Hasan, Md. Jahangir Alam, Jaroslav Kristof, Hiroyuki Niida, <u>Kazuo Shimizu</u> Presenter affiliation: Shizuoka University, Hamamatsu, Japan.	34
COX2 promotes immunotherapy resistance in melanoma by regulating ferroptosis and the immune microenvironment <u>Ningyue Sun</u> , Hao Wang, Lin He, Weinan Guo, Tianwen Gao, Chunying Li Presenter affiliation: Xijing Hospital, Xi'an, China.	35
Spatial proteomic mapping of the m⁶A regulatory network in the tumor-immune microenvironment <u>Xinshui Tan</u> , Berçin Yildiran, Jochen Utikal, Michaela Frye Presenter affiliation: German Cancer Research Center, Heidelberg, Germany.	36
Cancer cell outcompetes methionine to suppress T cell immunity Ting Li, <u>Zhenghai Tang</u> Presenter affiliation: University of Macau, Macau, China.	37
Treg-intrinsic IL-17A signaling constrains antitumor immunity in colorectal cancer <u>Xue Tong</u> , Yuan Zong, Wai Po Chong Presenter affiliation: Hong Kong Baptist University, Kowloon Tong, Hong Kong, China.	38

Strategies to reverse T cell exhaustion in tumors

Jing Wen, Yang-Xin Fu, Wenyan Wang

Presenter affiliation: Tsinghua University, Beijing, China.

39

***In situ* discovery of immune repertoire reveals antitumor immunity and therapeutic antibodies**

Haorui Zhang, Peiyu Wang, Yahui Zhao, Lukai Yang, Teng Xue, Linlin Liu, Xuelian Liu, Yanping Zhao, Zongxu Zhang, Jiahao Ma, Baige Zeng, Peng Zhang, Cunyu Wang, Deng Pan, Zhidong Gao, Zhihua Liu, Zexian Zeng

Presenter affiliation: Peking University, Academy for Advanced Interdisciplinary Studies, Beijing, China.

40

Disrupting a specific microRNA in regulatory T cells to activate anti-tumor responses

Yangnan Zhang, Karen Gu, Phil Darcy, Mark Chong

Presenter affiliation: St Vincent's Institute of Medical Research, Melbourne, Australia; University of Melbourne, Melbourne, Australia.

41

Uncovering the immune landscape of esophageal cancer—A single-cell atlas of the post-neoadjuvant chemioimmunotherapy microenvironment

Jiayong Xu, Peixuan Lv, Qingnan Zhao, Zheng Ruan

Presenter affiliation: Shanghai General Hospital, Shanghai, China.

42

An ac4C-programmed NAT10⁺ macrophage phenotype drives metastatic immune evasion in pancreatic ductal adenocarcinoma

Ximo Xu, Shaopeng Zhang, Tingting Kong, Jiang Long, Yan Zheng, Zhengjun Qiu

Presenter affiliation: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

43

SESSION 3 **TARGETING CELL DEATH FOR CANCER
IMMUNOTHERAPY**

Chairpersons: **Guido Kroemer**, Université Paris Cité, Paris, France
 Weiping Zou, University of Michigan Medical School,
 Ann Arbor, Michigan, USA

**Immunostimulatory and immunosuppressive damp dictating
immunosurveillance**

Guido Kroemer [20'+10']

Presenter affiliation: Université Paris Cité, Paris, France.

44

**Pharmacological targeting of protein kinase CK2 by the clinical-
stage CIGB-300 anticancer peptide induces immunogenic cell
death (ICD) features.**

Daylen Aguilar-Noriega, Xuan Wang, Yin Yi, Wen Li, Yasser Perera,
Nathan Yang, Silvio E. Perea [10'+5']

Presenter affiliation: China Cuba Biotechnology Joint Innovation
Center (CCBJIC), Yongzhou, China.

45

Ferroptosis in tumor immunity and therapy

Weiping Zou [20'+10']

Presenter affiliation: University of Michigan Medical School, Ann Arbor,
Michigan.

46

**Targeted TBK1 degradation rewires innate immune signalling to
promote inflammatory tumour cell death**

Tencho Tenev, Iona Ferguson, John J. Caldwell, Patrick R. Zanon,
Stephen T. Hallett, Natalia Serrano-Aparicio, Russell J. Wood, Shakil
Khan, Sidonie W. John, Rebecca Wilson, Matthew T. Warren, Yann-
Vai L. Bihan, Fiona Dziegiel, Agnieszka Konopacka, Rob L. van
Montfort, Henrik Daub, Zoran Rankovic, Pascal Meier [10'+5']

Presenter affiliation: The Institute of Cancer Research, London, United
Kingdom.

47

**IL1RAP adcs are efficacious against both primary and metastatic
disease in multiple oncofusion-driven cancers**

Hai-Feng Zhang, Edouard De Dreuzy, Yue Zhou Huang, Virginia
Adamiak, Qingfeng Huang, Seungmin Shin, Wei Li, Richard C.
Sainson, Poul H. Sorensen [10'+5']

Presenter affiliation: University of British Columbia, Vancouver,
Canada; BC Cancer Agency, Vancouver, Canada.

48

SESSION 4 **INTEGRATIVE STRATEGIES IN CANCER
IMMUNOTHERAPY**

Chairpersons: **Thomas Gajewski**, University of Chicago, Chicago,
Illinois, USA
 Ruihua Xu, Sun Yat-sen University Cancer Center,
Guangzhou, China

**Novel myeloid cell-targeted interventions to expand cancer
immunotherapy efficacy**

Thomas Gajewski [20'+10']

Presenter affiliation: University of Chicago, Chicago, Illinois. 49

**PD-L1 reverse signaling sustains the antimetastatic activity of
eosinophils in colorectal cancer**

Glenn De Lange, Kristina Handler, Alessandra Gurtner, Deeksha Raju,
Hassan Fazilaty, Isabelle C. Arnold [10'+5']

Presenter affiliation: University of Zürich, Zürich, Switzerland. 50

**Clinical and translational research on immunotherapy for GI
cancers**

Rui-Hua Xu [20'+10']

Presenter affiliation: Sun Yat-sen University Cancer Center,
Guangzhou, China. 51

**Targeting CD11b⁺ regulatory b cells via RAS/RAF/PI3K pathway
inhibition augments therapy response to immune checkpoint
blockade and CD40 agonism in metastatic melanoma**

Qianni Hu, Douglas B. Johnson, Ann Richmond, Chi Yan [10'+5']

Presenter affiliation: University of Manitoba, Winnipeg, Canada;
Vanderbilt University, Nashville, Tennessee; CancerCare Manitoba,
Winnipeg, Canada. 52

Break

**Adenosine signal axis engineering broadly enhances CAR-T cell
infiltration and therapeutic efficacy in solid tumors**

Xiaoqia Wang, Shiyu Sun, Ziwei Liang, Li Yan, Yang Xu [10'+5']

Presenter affiliation: Southern University of Science and Technology,
Shenzhen, China. 53

Intra-pancreatic adipose tissue induces immune evasion via thermogenesis in pancreatic cancer

Xinpeng Yin, Chengcheng Wang, Yupei Zhao [10'+5']

Presenter affiliation: Peking Union Medical College Hospital, Beijing, China.

54

Drug-packaging tumor microparticles—A polynomial immunotherapy

Bo Huang [20'+10']

Presenter affiliation: Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

55

WEDNESDAY, September 9—1:30 PM

Visit to Old Suzhou

WEDNESDAY, September 9—7:00 PM

SESSION 5 CANCER VACCINES

Chairpersons: **Kok Haw Jonathan Lim**, The University of Manchester & The Christie NHS Foundation Trust, Manchester, United Kingdom
Carlos-Filipe Pereira, Lund University, Lund, Sweden

Cross-presentation shapes cancer neoantigens visible to T cells

Kok Haw Jonathan Lim [20'+10']

Presenter affiliation: The University of Manchester, Manchester, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; The Francis Crick Institute, London, United Kingdom.

56

A global TCR discovery approach for immunotherapy of solid tumors based on a microfluidic platform

Felix Andres, Kyra Fischer, Maxim Emelianov, Pornpimol

Charoentong, Jingyu Yang, David Gomez-Zepeda, Frank Momburg, Marten Meyer, Stefan Tenzer, Inka Zoernig, Wolfram Osen, Oliver Zivanovic, Stefan Eichmueller [10'+5']

Presenter affiliation: German Cancer Research Center, Heidelberg, Germany.

57

Adjuvant-free recall of stem-like intratumoral virus-specific T cells sparks endogenous antitumor immunity

Saisi Qu, Yiqi Cai, Menglong Hu, Xuefeng He, Yuting Li, Wenbin Zhao, Yiding Chen, Wei Chen, Yushen Du [10'+5']

Presenter affiliation: Zhejiang University, Hangzhou, China. 58

Radiation promotes DNA mismatch repair heterogeneous tumors to initiate immune surveillance

Yang Pu [10'+5']

Presenter affiliation: Chinese Academy of Medical Sciences, Beijing, China. 59

Inducing immunogenic lymphoid niches across cancers by tumor-to-dendritic cell reprogramming.

Ervin Asic, Camille Chatelain, Gaia Fontanari, César P. Bucio, Linmeng Zhang, Maria Thrasyvoulou, Viktoria Karali, Tommaso Ballocci, Maria de Rosa Torres, Simon Rabreau, Katherine Hampton, Chaofan Fan, Xavier Catena, Johan Bengzon, Fábio F. Rosa, Göran B. Jönsson, Ilia Kurochkin, Carlos-Filipe Pereira [20'+10']

Presenter affiliation: Lund University, Lund, Sweden; Asgard Therapeutics AB, Lund, Sweden. 60

Local humoral evolution enables endogenous tumor antigen discovery

Xuefeng He, Zheyu Fang, Shuhang Hua, Jincheng Qiao, Huaijun Chen, Yingkuan Shao, Chao Ni, Yushen Du [10'+5']

Presenter affiliation: Zhejiang University School of Medicine, Hangzhou, China. 61

THURSDAY, September 10—9:00 AM

SESSION 6 PRIMARY AND ACQUIRED RESISTANCE TO CANCER IMMUNOTHERAPY

Chairpersons: **Yang-Xin Fu**, Tsinghua University, Beijing, China
Laurence Zitvogel, Université Paris-Saclay, Villejuif, France

Thymus senses gut dysbiosis through desaminotyrosine to rescue cancer immunosurveillance

Simon Thomas, Miguel Araujo-Voces, Meriem Messaoudene, Arielle Elkrief, Bertrand Routy, Lisa Derosa, Guido Kroemer, Laurence Zitvogel [20'+10']

Presenter affiliation: Université Paris-Saclay, Villejuif, France. 62

The immune strategies to convert cold to hot tumors to overcome immune resistances

Yang-Xin Fu [20'+10']

Presenter affiliation: Tsinghua University, Beijing, China. 63

Androgen signaling drives male immunotherapy resistance by sustaining TCF1 expression to restrict CD8+ T cell effector transition

Guangzhao Zhu, Yuanhui Zhao, Ruilin Wang [10'+5']

Presenter affiliation: Nanjing University, Nanjing, China. 64

Decoding immune feedback modulators for next-generation cancer immunotherapy

Jun Wang [20'+10']

Presenter affiliation: New York University Grossman School of Medicine, New York, New York. 65

KEAP1 functions as an intracellular checkpoint to modulate anti-cancer immunity through the regulation of a T cell-specific anti-oxidative stress response

Liam Baird, Lyu Xi, Ke Wang, Fumiki Katsuoka, Masayuki Yamamoto [10'+5']

Presenter affiliation: Tohoku University, Sendai, Japan. 66

THURSDAY, September 10—11:15 AM

SESSION 7 CYTOKINE, ANTIBODY AND CELL ENGINEERING IN CANCER IMMUNOTHERAPY

Chairperson: **Gabrielle Belz**, The University of Queensland, Brisbane, Australia

Empowering the anti-tumour capacity of immune cells

Gabrielled T. Belz [20'+10']

Presenter affiliation: The University of Queensland, Brisbane, Australia. 67

Translational development of tumor-selective self-replicating mRNA IL-12 therapeutics—Clinical experience with STX-001 and first-in-human development of STX-003

Jason J. Luke, Prashant Nambiar, Tasuku Kitada [10'+5']

Presenter affiliation: Strand Therapeutics, Boston, Massachusetts. 68

Functional masking of CD3 engagement via IL10 reprograms TCE-induced T cell dysfunction and enables durable solid tumor eradication

Xinxin Wang, Yang-Xin Fu, Zaopeng Yang [10'+5']

Presenter affiliation: Changping Laboratory, Beijing, China.

69

THURSDAY, September 10—2:00 PM

SESSION 8 NEW APPROACHES TO CANCER IMMUNOTHERAPY

Chairpersons: **Xin Lin**, Tsinghua University, Beijing, China
Zemin Zhang, Chongqing Medical University, Chongqing, China

Regulation of anti-tumour immunity by RNA-binding proteins

Osamu Takeuchi [20'+10']

Presenter affiliation: Kyoto University, Kyoto, Japan.

70

Developing TCR-based chimeric antigen receptor STAR for immunotherapy

Xin Lin [20'+10']

Presenter affiliation: Tsinghua University, Beijing, China.

71

Overcoming tumor heterogeneity with a versatile dual-mechanism CAR T cell platform for broad-spectrum solid tumor targeting

Bei Wang, Siti Nazihah Mohd Salleh, Yvonne Yeap, Eve Ngoh, Wen-Hsin Lee, Mun Kuen Soh, Cleve Yeow, Jyue Yuan Lim, Nur Izzah Nabilah Binte Hussein, Damien Tan, Andrea Pavesi, Giulia Adriani, Boon Cher Goh, Cheng-I Wang, Kong Peng Lam [10'+5']

Presenter affiliation: Agency for Science, Technology and Research, Singapore.

72

Multi-omic profiling uncovers ZC3H12C as a targetable regulator for adoptive T cell therapy

Jing Zhou, Lu Zhang, Yuting Gong, Jiasheng Wang, Xin Lin [10'+5']

Presenter affiliation: Changping laboratory, Beijing, China; Peking University, Beijing, China.

73

Break

Regulatory elements of the tumor microenvironment identified through pan-cancer single cell analysis

Zemin Zhang [20'+10']

Presenter affiliation: Chongqing Medical University, Chongqing, China.

74

Metabolite-driven lysine acylations—Rewiring macrophage functions

Yingming Zhao [20'+10']

Presenter affiliation: The University of Chicago, Chicago, Illinois.

75

Tumor-associated inflammation epigenetically reprograms eosinophil development during colorectal cancer progression

Glenn De Lange, James I. King, Ignacio Gonzalez Perez, Mounir Taha, Kristina Handler, Isabelle C. Arnold [10'+5']

Presenter affiliation: University of Zurich, Zurich, Switzerland.

76

THURSDAY, September 10—5:00 PM

COCKTAILS and BANQUET

FRIDAY, September 11

Departure